A novel cell therapy approach using cord blood-derived natural killer cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from the University of Texas MD Anderson Cancer Center.
Families facing a childhood cancer diagnosis experience a range of psychological, social, and emotional stressors, from anxiety to financial strain to sibling concerns.
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting urinary side effects after receiving radiation therapy.
Although lung cancer screening is recommended in the U.S. for certain individuals with a history of smoking, only 18% of eligible individuals in the U.S. get screened.
Researchers have identified a “master regulator” gene, ZNFX1, that may act as a biomarker to help guide treatment in future clinical trials involving patients with therapy-resistant ovarian cancer, according to a study recently published in Cancer Research.
Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation delayed KRAS-mutated PDAC development in mice, according to results of a study published in Cancer Research, a journal of the American Association for Cancer Research.
A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
In a prospective cohort study of more than 85,000 adults in the UK, researchers at the NIH and University of Oxford found that individuals who engaged in light- and moderate-to-vigorous-intensity daily physical activity had a lower risk of cancer than individuals who were more sedentary.
New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated non-small cell lung cancer. Highlights include:
Two recent studies by researchers from Regenstrief Institute and the Indiana University School of Medicine explore the effect of the pandemic on colorectal cancer screening tests and diagnostic colonoscopies in central Indiana.
